Reference

Design

This was a retrospective study from a database of patients who tested serologically positive for Epstein Barr virus (EBV) infection either untreated or managed with intravenous vitamin C (IVC) infusions at the Riordan Clinic in Wichita, Kansas. The dosages used were 7.5 g, 15 g, 25 g, and 50 g. The complete IVC protocols can be seen in Table 1. Glucose-6-phosphate dehydrogenase was assessed for all patients before beginning IVC.

Table 1. Complete Intravenous Vitamin C Protocolsa

Ascorbic Acid Dose (Vol)

Solution Volume

Volume of MgCl2

Infusion Rate

Infusion Time

7.5 g (15 cc)

250 cc lactated Ringer’s solution

1 cc

0.5-1.0 g/min

~30 min

15 g (30 cc)

250 cc lactated Ringer’s solution

1 cc

0.5-1.0 g/min

~30 min

25 g (50 cc)

500 cc lactated

Ringer’s solution

1 cc

0.5-1.0 g/min

~60 min

50 g (100 cc)

500 cc sterile water

2 cc

0.5-1.0 g/min

~90 min

a Protocols based on 2 previous studies.1,2

Participants

The study evaluated 218 patients between 1997 and 2006 who had clinically elevated levels of EBV (178 with elevated EBV viral capsid antigen [VCA] IgG and 40 with elevated EBV VCA IgM). One hundred and ten subjects had a diagnosis of chronic fatigue syndrome, with the remainder diagnosed with fatigue, acute infectious mononucleosis, or EBV infection. Other demographics were not provided by the authors.

Outcome Measures

The primary outcome measures were disease duration and reduction of viral antibody levels. Secondary measures were plasma levels of ascorbic acid and 25-hydroxycholecalciferol.

Key Findings

Of 35 subjects with sufficient follow-up, the average EBV VCA IgG level pretreatment was 80±55 arbitrary units (AU) and 46±43 AU posttreatment, an average improvement of approximately 40% (P=0.001). Thirty-two of the 35 subjects had decreased EBV VCA IgG posttreatment while 3 had increased EBV VCA IgG.

Data were further broken down into patients who did not receive IVC treatment (controls) and patients treated with 5 or more IVC treatments. The decrease in percentage in EBV VCA IgG over time was greater in those receiving 5 or more IVC treatments when compared to those receiving no treatment. There was a 17±13% decrease in EBV antibodies in the control group compared to 46±39% in the 5-or-more IVC group (P<0.002).

Of those patients treated with IVC, the percentage of reduction in EBV VCA IgG increased with the number of treatments received. The calculated change in the percentage of improvement was 2.7±0.7% per treatment (P<0.001).

Limitations

Demographic information was quite limited in this study. Other weaknesses included these issues: IVC treatment intervals were not provided, EBV symptomatology was not assessed, and there was wide variability in the subgroup receiving more than 5 treatments, which ranged from 5 to 23.

Clinical Implications

Positive EBV antibody serology rates have reached over 95% in all populations with a worldwide distribution.3 EBV is one of 8 known human herpesviruses first detected in 1964 from cultured human B lymphoid cells obtained from Burkitt lymphoma specimens in Africa.4 EBV infection is spread primarily by saliva, with the incubation period lasting from 4 to 8 weeks. The symptomatic primary EBV infection seen in otherwise healthy older children, adolescents, and young adults is commonly known as acute infectious mononucleosis (IM). IM may present with fever, pharyngitis, adenopathy, splenomegaly, malaise, and an atypical lymphocytosis.5,6

EBV has also been suspected as a pathogenic factor for various autoimmune diseases, including multiple sclerosis, rheumatoid diseases, autoimmune hepatitis, and inflammatory bowel disease. Pender proposes a unifying hypothesis suggesting that a genetically determined CD8+ T-cell (CD8) deficiency underlies the development of autoimmune diseases by impairing CD8 control of EBV infection. He also presents evidence that vitamin D deficiency is associated with a decreased proportion of CD8, cells suggesting that deprivation of sunlight and low levels of 25-hydroxycholecalciferol exacerbate the CD8 genetic deficiency and impair control of EBV infection.9

Table 2 describes common diagnostic laboratory workups for the diagnosis of EBV. In an acute infection, heterophile antibodies can be measured, providing the basis for the monospot rapid agglutination test. Antibodies to VCA IgG and VCA IgM are produced during the early symptom course and are more specific for EBV. IgG antibodies to EBV nuclear antibody (EBNA) appear 6 to 12 weeks after onset of symptoms and are elevated when the virus begins to establish latency. Both the VCA IgG antibody and EBNA persist for life. IgG antibodies to early antigen (EA) are present at the onset of clinical illness, can be elevated for several months and include two subsets: anti-D EA and anti-R EA.10-13

Uncomplicated primary EBV infections rarely require more than supportive therapy. Because corticosteroids, acyclovir, and antihistamines have not shown clinical benefit compared to placebo for the routine treatment of IM,8 naturopathic immune supportive therapy (eg, IVC) has the potential to provide individuals with symptomatic relief, improved recovery, and prevention from further viral complication.

Because of the large body of evidence implicating EBV in the etiology of a variety of human neoplasms, current clinical trials are looking at boosting immunity to EBV through immunization by targeting glycoprotein 350/220, one of the most abundant viral proteins present on the EBV surface. Trials have shown immunogenicity and a reduction in clinical symptoms, but immunization did not prevent EBV infection.14,15

Treatment of reactivated or persistently active EBV infections is often limited to the management of symptoms—with no obvious effect on morbidity and outcome—using antiviral agents, immunomodulating therapy (such as interferon gamma), interleukin-2, corticosteroids, cyclosporine A, immunoglobulins, and chemotherapeutic drugs.16,17 This presents an opportunity for further research utilizing naturopathic modalities such as IVC. Preliminary data for the treatment of chronic EBV infection are promising for vitamin D,18,19 curcumin,20 and Reishi mushrooms extracts.21

About the Authors

Landon Opunui, ND, is a naturopathic physician in his first year of residency at Lokahi Health Center, Kailua-Kona, Hawaii. Opunui received his naturopathic doctorate from Bastyr University, Kenmore, Washington, and his undergraduate degree from Loyola Marymount University, Los Angeles, California. He currently serves as the treasurer of the Hawaii Society of Naturopathic Physicians. For more information, visit DrOpunui.com.

Michael Traub, ND, DHANP, FABNO, completed pre-med studies at the University of California at Irvine. He graduated from National University of Naturopathic Medicine in 1981 and completed a residency there in Family Practice and Homeopathy. In 2006, Traub was honored with the American Association of Naturopathic Physicians (AANP) Physician of the Year Award in recognition for his many years of service, which included serving as AANP president from 2001 to 2003. His father was a dermatologist, and this inspired Traub to undertake extra study in this subject and become the leading expert in dermatology in the naturopathic profession. He has taught dermatology at 5 of the 7 accredited naturopathic medical schools in North America and is the author of Essentials of Dermatologic Diagnosis and Integrative Therapeutics. A fellow of the American Board of Naturopathic Oncology, Traub has been actively engaged in clinical research throughout most of his career and is currently a co-investigator in the Canadian/US Integrative Oncology Study. His most recent major publication, “Impact of Vitamin D3 Dietary Supplement Matrix on Clinical Response,” appears in a 2014 issue of the Journal of Clinical Endocrinology and Metabolism. Traub has served as medical director of Lokahi Health Center in Kailua Kona, Hawaii for the past 31 years.